The decision to impose this freeze is procedural in nature, and therefore is not subject to the notice and comment and effective date requirements of the Administrative Procedure Act, 5 U.S.C. 553(b)(A), (d). Moreover, the Media Bureau finds that there is good cause for not delaying the effect of these procedures until 30 days after publication in the Federal Register. Such a delay would be impractical, unnecessary, and contrary to the public interest because it would undercut the purposes of the freeze.

This action is taken by the Chief, Media Bureau pursuant to authority delegated by 47 CFR 0.283 of the Commission’s rules.

Federal Communications Commission.

Barbara Kreisman,
Chief, Video Division, Media Bureau.

[FR Doc. 2018–00286 Filed 1–9–18; 8:45 am]
BILLING CODE 6712–01–P

FEDERAL MARITIME COMMISSION

Notice of Agreement Filed

The Commission hereby gives notice of the filing of the following agreement under the Shipping Act of 1984. Interested parties may submit comments under the Shipping Act of 1984.

Title: Houston Marine Terminal Operators/Freight Handlers Agreement.

Parties: Ceres Gulf Inc.; Cooper/Ports America LLC; and SSA Gulf, Inc.

Filing Party: Shareen Larmond; West Gulf Maritime Association; 1717 Turning Basin Drive, Suite 200; Houston, Texas 77029.

Synopsis: The amendment updates the membership of the Agreement and makes other administrative changes.

By Order of the Federal Maritime Commission.

Dated: January 5, 2018.

Rachel E. Dickon,
Assistant Secretary.

[FR Doc. 2018–00286 Filed 1–9–18; 8:45 am]
BILLING CODE 6712–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC–2013–0015; Docket Number NIOSH 237–A]

National Framework for Personal Protective Equipment Conformity Assessment—Infrastructure

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of availability.

SUMMARY: NIOSH announces the availability of the following publication: National Framework for Personal Protective Equipment Conformity Assessment—Infrastructure.

DATES: The technical report was published on November 17, 2017.

ADDRESSES: This document may be obtained at the following link: https://www.cdc.gov/niosh/docs/2018-102/default.html.

FOR FURTHER INFORMATION CONTACT:
Maryann M. D’Alessandro, NIOSH, National Personal Protective Technology Laboratory, 626 Cochran Mill Road, Building 20, Pittsburgh, PA 15236, email address: bpj5@cdc.gov, (412) 386–6111 (not a toll free number).

SUPPLEMENTARY INFORMATION: In May 2011, NIOSH published a notice in the Federal Register [76 FR 28791] requesting comments on the recommendations issued by the Institute of Medicine in a report they electronically published in November 2010, titled, “Certifying Personal Protective Technologies.” In August 2013, NIOSH published a notice in the Federal Register [78 FR 49524] requesting comments on the draft NIOSH response to the Institute of Medicine recommendations, and announcing a public meeting which was held on September 17, 2013. In response to a request, NIOSH extended the public comment period to December 2, 2013. All comments received were reviewed and addressed where appropriate.

John Howard,
Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2018–00289 Filed 1–9–18; 8:45 am]
BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Guidance for Industry: Cooperative Manufacturing Arrangements for Licensed Biologics

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, we, or Agency) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by February 9, 2018.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202–395–7285, or emailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0629. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRASuff@ fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Guidance for Industry: Cooperative Manufacturing Arrangements for Licensed Biologics

OMB Control Number 0910–0629—Extension